Skip to main content

biote Corp

For the period ended Dec 31, 2023. Filed Mar 15, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 15, 2024

BTMD$1.08-2.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity (Deficit)

Total
Retained · Accumulated · Stockholders’ · Total
Additional · Earnings / · Other · Equity (Deficit) · Non- · Stockholders’
Members’ Equity · Class A Common Stock · Class V Voting Stock · Paid-in · (Accumulated · Comprehensive · Attributable to · controlling · Equity
Units · Amount · Shares · Amount · Shares · Amount · Capital · Deficit) · Income (Loss) · biote Corp. · Interest · (Deficit)
Balance at December 31, 2021982,800$——$——$—$—$4,165$(40)$4,125$—$4,125
Distributions———————(9,575)—(9,575)(3,311)(12,886)
Net income through May 26, 2022———————9,143—9,143—9,143
Other comprehensive income through May 26, 2022————————11—1
Business Combination: Reverse recapitalization on May 26, 2022(982,800)—7,574,271148,565,8245—(113,628)—(113,622)—(113,622)
Business Combination: Noncontrolling interest on May 26, 2022———————3,619343,653(3,653)—
Business Combination: Capitalized transaction costs———————(12,282)—(12,282)—(12,282)
Net loss after May 26, 2022———————(969)—(969)(6,850)(7,819)
Other comprehensive loss after May 26, 2022——————————(1)(1)
Share-based compensation———————82,180—82,180—82,180
Settlement of phantom equity rights———————(7,250)—(7,250)—(7,250)
Vesting of RSUs——1,950,557————(424)—(424)—(424)
Issuance of shares under SEPA——130,559————561—561—561
Balance at December 31, 2022—$-9,655,387$148,565,824$5$—$(44,460)$(5)$(44,459)$(13,815)$(58,274)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

Total
Accumulated · Stockholders’
Additional · Other · Deficit · Non- · Total
Class A Common Stock · Class V Voting Stock · Paid-in · Accumulated · Comprehensive · Attributable to · controlling · Stockholders’
Shares · Amount · Shares · Amount · Capital · Deficit · Loss · biote Corp. · Interest · Deficit
Balance at December 31, 20229,655,387$148,565,824$5$—$(44,460)$(5)$(44,459)$(13,815)$(58,274)
Distributions————————(8,694)(8,694)
Net income (loss)—————3,316—3,316(6,121)(2,805)
Other comprehensive income——————991019
Share-based compensation—————9,057—9,057—9,057
Vesting of RSUs1,250,512————(3,928)(6)(3,934)3,934—
Issuance of stock under purchase plans33,704(23)—(23)167144
Settlement of warrants3,088,473————15,986(1)15,9851,53017,515
Exercise of stock options105,049————2,043(3)2,040(1,620)420
Litigation settlement375,000————1,199—1,199—1,199
Exchanges of Class V voting stock19,746,7582(19,746,758)(2)—(17,455)(6)(17,461)17,460(1)
TRA liability—————4,874—4,874—4,874
Balance at December 31, 202334,254,883$328,819,066$3$—$(29,391)$(12)$(29,397)$(7,149)$(36,546)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.